MMED · MiniMed Group, Inc. · Metrics
$17.63
-0.17 (-0.93%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$5.00B
Shares
280.84M
Volume · Oct 20
4.41M
Avg daily vol (3M)
6.14M
MMED metrics
56 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$17.79
Market cap
$5.00B
Price action
20 metricsPrice change (1W)
-5.4%
Price change (30D)
-15.8%
Price change (3M)
+5.1%
Price change (6M)
+28.8%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
57.9%
Annualized volatility (3M)
51.9%
Beta
0.8
RSI (14D)
38.4
Price vs SMA 50
-12.9%
Price vs SMA 200
—
Avg volume (3M)
6.14M
Relative volume
2.9
Average dollar volume
$116.34M
Company
3 metricsSector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
280.84M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.5×
reciprocal yield 65.6%
P / book
1.4
reciprocal yield 73.7%
FCF yield
-6.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-6.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-09-01
Profitability
9 metricsGross margin
53.9%
Operating margin
-5.3%
Trailing 12 months
Net margin
-10.7%
Gross profit (TTM)
$1.74B
Operating profit (TTM)
−$172.00M
Net income (TTM)
−$314.00M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-9.8%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+16.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.22B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-8.7%
Return on assets
-6.7%
Debt / equity
—
Current ratio
1.8
EBITDA (TTM)
−$14.00M
Free cash flow (TTM)
−$316.00M
Quick ratio
1.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$207.00M
Latest balance sheet
Cash & equivalents
$207.00M
Total assets
$4.72B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$105.00M
Capital expenditures (TTM)
$211.00M
R&D (TTM)
$438.00M
SG&A (TTM)
$1.21B
Stock compensation (TTM)
$47.00M
R&D / revenue
13.6%
Stock compensation / revenue
1.5%
Ownership (13F)
9 metrics13F filers
99
13F filer change QoQ
+42
Institutional ownership
13.4%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—
Ownership (registered funds)
1 metricsIndex-fund ownership
0.8%
Short interest
3 metricsShort interest
6.5%
Latest settlement · 5.9 days to cover
Days to cover
5.9d
Short-squeeze score
76 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—